Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
2,435
Views
28
CrossRef citations to date
0
Altmetric
Editorial

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer

Oliver Keppa Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, FranceORCID Iconhttps://orcid.org/0000-0002-6081-9558
ORCID Icon,
Laurence Zitvogelc Gustave Roussy Cancer Center, Inserm U1015, Villejuif, France;d Gustave Roussy Cancer Center, Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France;e Faculty of Medicine, Université Paris Saclay, Le Kremlin-Bicêtre, France;f Chinese Academy of Medical Sciences, Suzhou Institute for Systems Medicine, Suzhou, ChinaORCID Iconhttps://orcid.org/0000-0003-1596-0998
ORCID Icon &
Guido Kroemera Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France;f Chinese Academy of Medical Sciences, Suzhou Institute for Systems Medicine, Suzhou, China;g Pôle De Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France;;h Karolinska Institutet, Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, SwedenCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9334-4405
ORCID Icon
Article: 1795995 | Received 09 Jul 2020, Accepted 10 Jul 2020, Published online: 21 Jul 2020

Figures & data

Figure 1. Clinical development of lurbinectedin for the treatment of small-cell lung carcinoma. a. Current FDA-approved use of lurbinectedin, as a salvage therapy after failure of platinum compound-based chemotherapy. b. Hypothetical use of lurbinectedin as a first-line treatment. c. Hypothetical combination of lurbinectedin used in first or second line with PD-1/PD-L1-blocking antibodies.

Figure 1. Clinical development of lurbinectedin for the treatment of small-cell lung carcinoma. a. Current FDA-approved use of lurbinectedin, as a salvage therapy after failure of platinum compound-based chemotherapy. b. Hypothetical use of lurbinectedin as a first-line treatment. c. Hypothetical combination of lurbinectedin used in first or second line with PD-1/PD-L1-blocking antibodies.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.